Q-omics provides the consensus-scored HTR1D profile across patient tissues and cancer cell-line models. HTR1D expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HTR1D is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, HTR1D RNA expression shows 14,567 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where HTR1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR1D survival associations across molecular data types. HTR1D RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR1D RNA expression–survival associations across cancer types. High HTR1D expression shows unfavorable associations in HNSC, LIHC, ACC, LGG and LUAD, but favorable associations in BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for HTR1D RNA expression.
This table summarizes HTR1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HTR1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR1D shows higher tumor expression in HNSC, COAD, THCA, LUAD, STAD and LIHC. The HNSC box plot shows higher HTR1D RNA expression in tumor versus normal tissue (log2 FC = +1.116, t-test p < 0.001).
This table shows molecular features associated with HTR1D in patient tissues and cancer cell lines. In patient samples, HTR1D shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
